108 related articles for article (PubMed ID: 1325463)
1. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Verweij J; Planting A; van der Burg M; Stoter G
J Cancer Res Clin Oncol; 1992; 118(8):606-8. PubMed ID: 1325463
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Planting AS; Stoter G; Verweij J
Eur J Cancer; 1993; 29A(4):518-9. PubMed ID: 8435202
[TBL] [Abstract][Full Text] [Related]
3. Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Pronk LC; Planting AS; Oosterom R; Drogendijk TE; Stoter G; Verweij J
Eur J Cancer; 1994; 30A(7):1019-22. PubMed ID: 7946566
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
Verweij J; Gandia D; Planting AS; Stoter G; Armand JP
Eur J Cancer; 1993; 29A(5):778-9. PubMed ID: 8471342
[No Abstract] [Full Text] [Related]
5. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
Crul M; Rosing H; de Klerk GJ; Dubbelman R; Traiser M; Reichert S; Knebel NG; Schellens JH; Beijnen JH; ten Bokkel Huinink WW
Eur J Cancer; 2002 Aug; 38(12):1615-21. PubMed ID: 12142051
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Mahieu-Renard L; Richard MA; Dales JP; Buscaylet S; Lagrassa S; Grob JJ
Ann Dermatol Venereol; 2005 Apr; 132(4):346-8. PubMed ID: 15886562
[TBL] [Abstract][Full Text] [Related]
7. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
8. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.
Koukourakis MI; Koukouraki S; Giatromanolaki A; Archimandritis SC; Skarlatos J; Beroukas K; Bizakis JG; Retalis G; Karkavitsas N; Helidonis ES
J Clin Oncol; 1999 Nov; 17(11):3512-21. PubMed ID: 10550149
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Verweij J; Krzemieniecki K; Kok T; Poveda A; van Pottelsberghe C; van Glabbeke M; Mouridsen H
Eur J Cancer; 1993; 29A(2):208-9. PubMed ID: 8422284
[TBL] [Abstract][Full Text] [Related]
10. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Gerrits CJ; Burris H; Schellens JH; Planting AS; van den Burg ME; Rodriguez GI; van Beurden V; Loos WJ; Hudson I; Fields S; Verweij J; von Hoff DD
Eur J Cancer; 1998 Jun; 34(7):1030-5. PubMed ID: 9849451
[TBL] [Abstract][Full Text] [Related]
11. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
Fujii M; Tomita K; Nishijima W; Tsukuda M; Hasegawa Y; Ishitoya J; Yamane H; Homma A; Tomita T
Jpn J Clin Oncol; 2010 Mar; 40(3):214-21. PubMed ID: 19934112
[TBL] [Abstract][Full Text] [Related]
13. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
16. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
Dowell JE; Sinard R; Yardley DA; Aviles V; Machtay M; Weber RS; Weinstein GS; Chalian AA; Carbone DP; Rosenthal DI
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):97-101. PubMed ID: 10210547
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
19. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
